Kymera Therapeutics (KYMR)
(Real Time Quote from BATS)
$46.99 USD
-0.08 (-0.17%)
Updated Nov 5, 2024 10:22 AM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
KYMR 46.99 -0.08(-0.17%)
Will KYMR be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYMR
Kymera Q3 Loss Narrower Than Expected, Pipeline in Focus
Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Lags Revenue Estimates
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Kymera's IND Application for STAT6 Degrader Gets FDA Clearance
Other News for KYMR
Analysts Conflicted on These Healthcare Names: Penumbra (PEN), Kymera Therapeutics (KYMR) and NovoCure (NVCR)
Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Halozyme (HALO) and Kymera Therapeutics (KYMR)
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
The Latest Analyst Ratings For Kymera Therapeutics
Kymera Therapeutics price target raised to $52 from $45 at Guggenheim